Proteinuria in COVID-19: prevalence, characterization and prognostic role.


Journal

Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268

Informations de publication

Date de publication:
04 2021
Historique:
received: 25 07 2020
accepted: 18 11 2020
pubmed: 24 1 2021
medline: 22 4 2021
entrez: 23 1 2021
Statut: ppublish

Résumé

Proteinuria has been commonly reported in patients with COVID-19. However, only dipstick tests have been frequently used thus far. Here, the quantification and characterization of proteinuria were investigated and their association with mortality was assessed. This retrospective, observational, single center study included 153 patients, hospitalized with COVID-19 between March 28th and April 30th, 2020, in whom total proteinuria and urinary α According to the Kidney Disease Improving Global Outcomes staging, 14% (n = 21) of the patients had category 1 proteinuria (< 150 mg/g of urine creatinine), 42% (n = 64) had category 2 (between 150 and 500 mg/g) and 44% (n = 68) had category 3 proteinuria (over 500 mg/g). Urine α Proteinuria is frequent in patients with COVID-19. Its characterization suggests a tubular origin, with increased urinary α

Sections du résumé

BACKGROUND
Proteinuria has been commonly reported in patients with COVID-19. However, only dipstick tests have been frequently used thus far. Here, the quantification and characterization of proteinuria were investigated and their association with mortality was assessed.
METHODS
This retrospective, observational, single center study included 153 patients, hospitalized with COVID-19 between March 28th and April 30th, 2020, in whom total proteinuria and urinary α
RESULTS
According to the Kidney Disease Improving Global Outcomes staging, 14% (n = 21) of the patients had category 1 proteinuria (< 150 mg/g of urine creatinine), 42% (n = 64) had category 2 (between 150 and 500 mg/g) and 44% (n = 68) had category 3 proteinuria (over 500 mg/g). Urine α
CONCLUSIONS
Proteinuria is frequent in patients with COVID-19. Its characterization suggests a tubular origin, with increased urinary α

Identifiants

pubmed: 33484426
doi: 10.1007/s40620-020-00931-w
pii: 10.1007/s40620-020-00931-w
pmc: PMC7823174
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

355-364

Commentaires et corrections

Type : CommentIn

Références

Clin Chem Lab Med. 2014 Apr;52(4):537-46
pubmed: 24243749
J Am Soc Nephrol. 2020 Aug;31(8):1683-1687
pubmed: 32371536
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Am Soc Nephrol. 2019 Oct;30(10):1785-1805
pubmed: 31506289
Nephron. 2020;144(5):213-221
pubmed: 32203970
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Lancet. 2020 May 16;395(10236):e87-e88
pubmed: 32423587
Nat Commun. 2021 May 4;12(1):2506
pubmed: 33947851
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
J Clin Pathol. 1983 Mar;36(3):253-9
pubmed: 6186698
Kidney Int. 2020 Aug;98(2):505-506
pubmed: 32446936
Kidney Int. 2020 Jul;98(1):241
pubmed: 32471641
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
J Am Soc Nephrol. 2020 Jun;31(6):1157-1165
pubmed: 32345702
Clin Biochem Rev. 2016 Feb;37(1):17-26
pubmed: 27057075
J Am Soc Nephrol. 2020 Jul;31(7):1380-1383
pubmed: 32366514
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
J Nephrol. 2021 Apr;34(2):411-432
pubmed: 32328900
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Med Virol. 2020 Sep;92(9):1676-1680
pubmed: 32330305
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Clin Infect Dis. 2020 Nov 5;71(8):1962-1968
pubmed: 32472676
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651

Auteurs

Justine Huart (J)

Department of Nephrology-Dialysis-Transplantation, Service de Dialyse, CHU Sart Tilman, University of Liège (CHU ULiege), 4000, Liège, Belgium.
Groupe Interdisciplinaire de Géno-protéomique Appliquée, Cardiovascular Sciences, University of Liège, Liège, Belgium.

Antoine Bouquegneau (A)

Department of Nephrology-Dialysis-Transplantation, Service de Dialyse, CHU Sart Tilman, University of Liège (CHU ULiege), 4000, Liège, Belgium.

Laurence Lutteri (L)

Department of Clinical Chemistry, CHU Sart Tilman, University of Liège (CHU ULiege), Liège, Belgium.

Pauline Erpicum (P)

Department of Nephrology-Dialysis-Transplantation, Service de Dialyse, CHU Sart Tilman, University of Liège (CHU ULiege), 4000, Liège, Belgium.
Groupe Interdisciplinaire de Géno-protéomique Appliquée, Cardiovascular Sciences, University of Liège, Liège, Belgium.

Stéphanie Grosch (S)

Department of Nephrology-Dialysis-Transplantation, Service de Dialyse, CHU Sart Tilman, University of Liège (CHU ULiege), 4000, Liège, Belgium.

Guillaume Résimont (G)

Department of Nephrology-Dialysis-Transplantation, Service de Dialyse, CHU Sart Tilman, University of Liège (CHU ULiege), 4000, Liège, Belgium.

Patricia Wiesen (P)

Department of Intensive Care, CHU Sart Tilman, University of Liège (CHU ULiege), Liège, Belgium.

Christophe Bovy (C)

Department of Nephrology-Dialysis-Transplantation, Service de Dialyse, CHU Sart Tilman, University of Liège (CHU ULiege), 4000, Liège, Belgium.

Jean-Marie Krzesinski (JM)

Department of Nephrology-Dialysis-Transplantation, Service de Dialyse, CHU Sart Tilman, University of Liège (CHU ULiege), 4000, Liège, Belgium.
Groupe Interdisciplinaire de Géno-protéomique Appliquée, Cardiovascular Sciences, University of Liège, Liège, Belgium.

Marie Thys (M)

Department of Medico-Economic Information, CHU Sart Tilman, University of Liège (CHU ULiege), Liège, Belgium.

Bernard Lambermont (B)

Department of Intensive Care, CHU Sart Tilman, University of Liège (CHU ULiege), Liège, Belgium.

Benoît Misset (B)

Department of Intensive Care, CHU Sart Tilman, University of Liège (CHU ULiege), Liège, Belgium.

Hans Pottel (H)

Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium.

Christophe Mariat (C)

Nephrology, Dialysis and Renal Transplantation Department, Hôpital Nord, CHU de Saint-Etienne, Jean Monnet University, COMUE Université de Lyon, Lyon, France.

Etienne Cavalier (E)

Department of Clinical Chemistry, CHU Sart Tilman, University of Liège (CHU ULiege), Liège, Belgium.

Stéphane Burtey (S)

Center of Nephrology and Renal Transplantation, Public Assistance of the Hospitals of Marseille, Marseille, France.
Aix-Marseille University, INSERM, INRA, C2VN, Marseille, France.

François Jouret (F)

Department of Nephrology-Dialysis-Transplantation, Service de Dialyse, CHU Sart Tilman, University of Liège (CHU ULiege), 4000, Liège, Belgium.
Groupe Interdisciplinaire de Géno-protéomique Appliquée, Cardiovascular Sciences, University of Liège, Liège, Belgium.

Pierre Delanaye (P)

Department of Nephrology-Dialysis-Transplantation, Service de Dialyse, CHU Sart Tilman, University of Liège (CHU ULiege), 4000, Liège, Belgium. pierre_delanaye@yahoo.fr.
Department of Nephrology-Dialysis-Apheresis, Hopital Universitaire Caremeau, Nimes, France. pierre_delanaye@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH